+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years +
All Genders
ID07803185

Longitudinal Study of Anhedonia and Emotional Eating in Adults Starting GLP-1 Receptor Agonist Therapy for Weight Loss

Led by TC Erciyes University · Updated on 2026-09-03

60

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying adults with obesity to understand changes in anhedonia and emotional eating behaviors when starting treatment with glucagon-like peptide-1 GLP-1 receptor agonists for weight loss. This observational study focuses on how these medications, which affect appetite and reward-related brain areas, impact emotional and reward-related eating over time. Participants newly starting GLP-1 receptor agonist therapy are assessed at the beginning of treatment and again after six months. These assessments use standardized questionnaires to measure anhedonia with the Dimensional Anhedonia Rating Scale DARS and emotional eating patterns with the Emotional Eating Scale EES. The study also tracks treatment adherence, dosage changes, appetite variations, and any adverse effects. During the study, participants attend two main evaluation visits one at treatment start and another six months later. At these visits, researchers collect demographic information, questionnaire responses, and clinical data to monitor changes. The main outcome is the change in anhedonia scores over six months, with emotional eating changes as a secondary measure. The study is conducted at a single center and ends in December 2026.

CONDITIONS

Brief Title

Evaluation of Anhedonia and Emotional Eating in Individuals Using GLP-1 Receptor Agonists

Research Team

H

Hasan Durmuş, MD, Assoc. Prof.

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here